what is the difference
Argireline vs SNAP-8
One cosmetic peptide built as an extension of another, sold on the same mechanism, with published records of very different sizes.
Argireline is the trade name for acetyl hexapeptide-8, a six amino acid peptide applied to the skin. It is patterned on the end of SNAP-25, part of the SNARE complex that nerve endings assemble in order to release acetylcholine, their signal to a muscle. The proposal is that the peptide gets in the way of that assembly, the same pathway a botulinum toxin acts on at a vastly higher potency and by injection rather than from a cream [3].
SNAP-8 is the trade name for acetyl octapeptide-3, an eight amino acid extension of that sequence, sold on the same reasoning: same mechanism, two more residues, more potency. Both are listed cosmetic ingredients, lawfully sold and advertised on how skin looks [6] [7].
Not medical advice
This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.
Reviewed against editorial standards Updated
The short answer
Argireline is the parent and SNAP-8 is the extension. Acetyl hexapeptide-8 has one randomised, placebo-controlled human trial: 60 Chinese subjects with periorbital wrinkles over four weeks, allocated three to one, which puts roughly 15 people on placebo [2]. A 2025 review concludes that its low skin penetration limits bioavailability and that whether it reaches neuromuscular junctions remains uncertain [1].
No published trial tests acetyl octapeptide-3 on its own. A PubMed search for that INCI name on 2 August 2026 returned exactly two records [8], and both are multi-ingredient microneedle patch studies, where a microneedle patch punctures the outer layer of skin [4] [5]. Every comparative potency statement about the octapeptide traces to unpublished manufacturer material.
Side by side
| Property | Argireline (acetyl hexapeptide-8) | SNAP-8 (acetyl octapeptide-3) |
|---|---|---|
| What it is | A six amino acid peptide with an acetyl group at the front, patterned on the N-terminal end of SNAP-25 | An eight amino acid peptide built as an extension of that same sequence |
| INCI name on a label | Acetyl hexapeptide-8, formerly acetyl hexapeptide-3. Both names remain in circulation for the same ingredient | Acetyl octapeptide-3. The number belongs to the octapeptide series, not to the older hexapeptide name |
| Published human trials of the ingredient on its own | One: a randomised, placebo-controlled study in 60 Chinese subjects over four weeks, allocated three to one, so roughly 15 people on placebo [2] | None. A PubMed search for the INCI name returned two records on 2 August 2026, neither testing this peptide alone [8] |
| How it was delivered in the studies | A topical formulation, so the permeability question a 2025 review raises applies directly [1] | A microneedle patch in both records, puncturing the outer layer of skin: the barrier the permeability argument concerns |
| Legal position in the United States | A listed cosmetic ingredient, lawfully sold and advertised on appearance, with registration, listing, safety substantiation and adverse event duties, and labelling at 21 CFR part 701 [6] [7] [9] | The same, and nothing in it requires evidence of effect |
| Evidence grade on this site | Not graded here. The source review a grade is derived from has not been run | Not graded here, same reason |
Why the two get mixed up
The first trap is inside one ingredient. Argireline was listed as acetyl hexapeptide-3 under the older international nomenclature and is now acetyl hexapeptide-8, and both names still appear on labels and in search results for the same compound. A reader who learns those two are one thing then meets acetyl octapeptide-3 and reads the trailing 3 as the same series number returning. It is not: octapeptide and hexapeptide are separate INCI families, numbered within each.
The second is that SNAP-8 is genuinely built from Argireline: an eight amino acid extension of the same sequence, sold on the same SNARE-complex reasoning, so a description of one is very nearly a description of the other. The abbreviation adds to it, because SNAP-8 sounds like a version of SNAP-25, the protein the mechanism story is about, and the two get run together in casual writing.
What the confusion costs is specific. The hexapeptide's trial gets read across to the extension as though a longer chain inherits it, and the extension's potency claim gets read back onto the parent as though a comparison had been run. Evidence about a different molecule never transfers here, and a two residue extension is a different molecule.
What the published record covers for each
The acetyl hexapeptide-8 record is one trial, worth reading at the level of its arms rather than its headline. Sixty Chinese subjects with periorbital wrinkles were randomised over four weeks against placebo, allocation three to one in favour of the active arm, which leaves roughly 15 people on placebo. Subjective assessment reported a total anti-wrinkle response of 48.9 percent in the active group against 0 percent on placebo, and silicone replicas analysed by a wrinkle-analysis instrument showed decreased roughness parameters in the active group at p below 0.01 [Human RCT] [2].
Twelve years later, a 2025 review of the same ingredient's permeability and efficacy concludes that its low skin penetration limits its bioavailability and that whether it reaches neuromuscular junctions remains uncertain [In-vitro] [1]. That is the open question underneath the trial: an ingredient can produce a measured change in a wrinkle-analysis parameter without anyone establishing that it arrives where the mechanism story says it acts.
The acetyl octapeptide-3 record is smaller than most readers expect, and the search was re-run for this page rather than taken on trust. A PubMed search for acetyl octapeptide-3 on 2 August 2026 returned exactly two records, and neither tests the peptide on its own [Anecdote] [8]. The first is a clinical evaluation of a dissolving microneedle patch carrying hyaluronic acid, acetyl octapeptide-3, an ascorbic acid derivative and a lysophosphatidic acid salt in 24 subjects, comparator a hyaluronic-acid-only patch on the other eye [4]. The second is a 12 week single-centre study of hyaluronic acid microneedle patches carrying five actives including acetyl octapeptide-3, with no placebo arm [5].
Two things follow, and both matter more than whatever either study reported. Neither can attribute a result to acetyl octapeptide-3, because the peptide arrived inside a mixture and the comparator differed by more than one ingredient [Anecdote] [4] [5]. And the delivery method in both is a microneedle patch, which punctures the outer layer of skin: the exact barrier the permeability argument in this category is about. A peptide delivered through holes made in the skin is not evidence about the same peptide in a cream, and the 2025 review of the related hexapeptide makes that point [1].
Which leaves the potency claim, the reason most people arrive at this comparison. Every statement ranking acetyl octapeptide-3 above acetyl hexapeptide-8 traces to unpublished supplier material rather than to a study anyone can read, and no head to head has been published in any design. The class reviews set out the shared mechanism and do not resolve it [Anecdote] [1] [3].
Our takeThe parent has one small trial with about fifteen people on placebo, and a 2025 review still asking whether the molecule gets deep enough. The extension is sold as the one that gets there better, and both its published records reached skin through holes punched in it.
Frequently asked questions
Is SNAP-8 stronger than Argireline?
No published study compares them. Every comparative potency statement in circulation traces to unpublished supplier material, and the class reviews describe the shared mechanism without resolving the ranking [1] [3]. A PubMed search for acetyl octapeptide-3 on 2 August 2026 returned two records, neither of which tested the peptide on its own [8].
Why did acetyl hexapeptide-3 become acetyl hexapeptide-8?
The international nomenclature for the ingredient was revised and the compound is the same. Both names remain in circulation on labels and in search results, which makes this one of the easier alias traps in the category to fall into.
Is Argireline the same as an injected muscle relaxant?
No. Acetyl hexapeptide-8 is a six amino acid peptide applied to the skin, patterned on part of the SNARE complex, at a potency nowhere near that of a botulinum toxin, and a 2025 review still describes it as uncertain whether it reaches a neuromuscular junction at all [1]. The comparison is a marketing frame rather than an equivalence.
Do microneedle patch studies count as evidence for a peptide in a cream?
They answer a different question. A microneedle patch punctures the outer layer of skin, the barrier the permeability debate concerns. Both published records naming acetyl octapeptide-3 used patches and delivered several actives at once [4] [5], so neither can attribute anything to that peptide in a topical formulation.
Are both lawful to sell in the United States?
Yes. Both are listed cosmetic ingredients, and a product containing either may be sold provided the seller registers the facility, lists the product, holds safety substantiation records and reports serious adverse events [6] [7], with labelling under 21 CFR part 701 [9]. Claims must be about appearance rather than about a structure or function of the body, and nothing requires evidence of effect.
References
- Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025. PMID 40565185 DOI 10.3390/ijms26125722
- Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013. PMID 23417317 DOI 10.1007/s40257-013-0009-9
- Skibska A, Perlikowska R. Signal Peptides - Promising Ingredients in Cosmetics. Curr Protein Pept Sci. 2021. PMID 34382523 DOI 10.2174/1389203722666210812121129
- Shin JY, Han D, Yoon KY, Jeong DH, Park YI. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol. 2024. PMID 39082657 DOI 10.5021/ad.23.136
- Avcil M, Akman G, Klokkers J, Jeong D, Çelik A. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol. 2020. PMID 31134751 DOI 10.1111/jocd.13009
- United States Congress. Consolidated Appropriations Act, 2023, Public Law 117-328, enacted 29 December 2022. Division FF, title III, subtitle E is the Modernization of Cosmetics Regulation Act of 2022, which adds subchapter VI of the Federal Food, Drug, and Cosmetic Act. govinfo. 2022. Source document
- Office of the Law Revision Counsel, United States House of Representatives. Federal Food, Drug, and Cosmetic Act, title 21 of the United States Code: section 321 for the definitions of drug and cosmetic, and subchapter VI sections 364 to 364d for cosmetic definitions, adverse events, registration and product listing, and safety substantiation. Checked 2 August 2026. United States Code. 2026. Source document
- US National Library of Medicine. PubMed, searched for the term acetyl octapeptide-3 on 2 August 2026. The search returned two records, PMID 39082657 and PMID 31134751, both of them studies of multi-ingredient microneedle patches. No record testing the peptide on its own was returned. PubMed. 2026. Source document
- Office of the Federal Register and Government Publishing Office. Cosmetic labeling, title 21 of the Code of Federal Regulations, part 701. Checked 2 August 2026. Electronic Code of Federal Regulations. 2026. Source document